ImmuCell amends Norbrook agreement; termination March 31, 2026 if FDA approval not received by Feb 28, 2026

IMMUCELL CORP /DE/

Norbrook will complete manufacture of current in-process inventory.
Agreement terminates March 31, 2026, subject to terms.
If FDA approval for Re-Tain not received by Feb 28, 2026, agreement expires and Norbrook invoices Final Balance.
Amendment continues other terms of the Development Services and Commercial Supply Agreement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.